What is the primary treatment for central neurocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Primary Treatment for Central Neurocytoma

Maximal safe surgical resection is the primary treatment for central neurocytoma, with gross total resection (GTR) providing the best long-term tumor control and survival outcomes. 1, 2, 3

Surgical Approach

Complete surgical excision should be the goal whenever safely achievable, as GTR is the most important therapeutic modality and confers superior long-term outcomes compared to subtotal resection (STR). 1, 3

Surgical Technique Options

  • Transcortical approach or interhemispheric transcallosal approach are both acceptable, with no significant differences in functional outcomes between the two methods. 3
  • Endoscopic-assisted resection can be considered for select cases, particularly posterior third ventricle locations, offering a minimally invasive option that avoids craniotomy-related morbidity. 4
  • Postoperative MRI with and without contrast should be obtained within 24-72 hours after surgery to document extent of resection. 5

Expected Outcomes

  • GTR is achievable in approximately 54% of cases. 3
  • The 5-year and 10-year overall survival rates are 93.3% and 85.4% respectively. 3
  • The 5-year and 10-year progression-free rates are 73.4% and 57.5%. 3

Management After Incomplete Resection

For patients with subtotal resection or residual tumor, adjuvant radiotherapy should be considered to improve local tumor control, as the extent of resection significantly impacts progression-free survival. 1, 3

Radiation Options

  • Stereotactic radiosurgery (SRS) is preferred for smaller residual tumor volumes or recurrences, providing safe and effective adjuvant therapy while avoiding long-term side effects of conventional radiotherapy in young patients. 6, 1
  • Standard external beam radiotherapy can be added after STR, or radiation can be delayed until tumor progression occurs. 1
  • Focused radiosurgery achieves complete response with tumor size reduction in recurrent cases. 6

Important Caveat

While complete radiographic tumor resection may be achieved initially, approximately 8-9% of patients experience tumor progression despite treatment, requiring long-term surveillance. 3

Role of Observation

Observation alone may be appropriate only after confirmed GTR, as central neurocytomas are WHO grade II tumors with a tendency to recur. 3 Serial MRI follow-up is essential, as local tumor progression can occur 9-25 months after initial surgery. 6

Limited Role of Chemotherapy

Chemotherapy is not considered a primary treatment modality for central neurocytoma. 2 It may be used as salvage therapy for recurrent tumors that cannot be resected and have already been radiated, though long-term responses have not been reported. 1

Prognostic Factors

  • MIB-1 Labeling Index appears more useful than histological features of anaplasia in predicting relapse and prognosis. 1, 2
  • Synaptophysin positivity is a key histological marker for diagnosis. 2
  • The extent of initial resection is the most critical factor determining local control rates. 3

References

Research

Central neurocytoma: a review.

Journal of neuro-oncology, 2004

Research

Endoscopic removal of a central neurocytoma from the posterior third ventricle.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.